SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 6.2% Stake in Spyre Therapeutics
Beneficial Ownership Report
RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a 6.2% beneficial ownership stake in Spyre Therapeutics, Inc. as of December 31, 2024.
Summary
- RTW Investments, LP, a Delaware limited partnership, and Roderick Wong, M.D., its Managing Partner and Chief Investment Officer, are the reporting persons.
- The filing pertains to Common Stock, par value $0.0001 per share, of Spyre Therapeutics, Inc.
- The reporting persons collectively beneficially own 3,621,996 shares of Spyre Therapeutics, Inc. common stock.
- This ownership represents 6.2% of the company's outstanding common stock.
- Both RTW Investments, LP and Dr. Roderick Wong share voting and dispositive power over all 3,621,996 shares.
- The percentage of class is calculated based on 58,670,608 shares outstanding as of November 18, 2024, as reported in the company's prospectus filed on November 19, 2024.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects. The disclosure of a significant institutional stake is a neutral event in itself, though it may be interpreted positively by some investors.
Positives
- Institutional investor RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a significant 6.2% stake in Spyre Therapeutics, Inc., indicating a notable investment position by a specialized healthcare investment firm.
Future Outlook
NA
Industry Context
This filing indicates significant institutional investment interest in Spyre Therapeutics, Inc., a company operating in the therapeutics sector. Such disclosures are common as investment funds adjust their portfolios and report their holdings in publicly traded companies, reflecting ongoing capital allocation within the biotechnology and pharmaceutical industries.
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional investor (RTW Investments, LP) holding 6.2% of common stock, which may influence market perception and trading activity and signal confidence from a specialized investment firm.
Key Dates
| Date | Description |
|---|---|
| 2024-11-18 | Date as of which 58,670,608 shares outstanding were reported in the company's prospectus. |
| 2024-11-19 | Date of the company's prospectus filing pursuant to Rule 424(b)(5). |
| 2024-12-31 | Date of event which requires the filing of this statement (end of reporting period). |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Spyre Therapeutics, RTW Investments, Roderick Wong, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology, healthcare investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.